A Phase 1/2 Multi-Center Study Evaluating the Safetyand Efficacy of KTE-X19 in Pediatric and AdolescentSubjects with Relapsed/Refractory B-precursor AcuteLymphoblastic Leukemia or Relapsed/Refractory B-CellNon-Hodgkin Lymphoma (ZUMA-4)
MD Anderson Study Status
Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.